Christopher A. Kroeger - 25 Oct 2025 Form 3 Insider Report for MapLight Therapeutics, Inc. (MPLT)

Role: Chief Executive Officer, Director
Signature: /s/ Kristopher L. Hanson, Attorney-in-Fact
Issuer symbol: MPLT
Transactions as of: 25 Oct 2025
Net transactions value: $0
Form type: 3
Filing time: 27 Oct 2025, 16:37:54 UTC
Next filing: 28 Oct 2025
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Kroeger Christopher A.	Chief Executive Officer, Director	C/O MAPLIGHT THERAPEUTICS, INC., 800 CHESAPEAKE DRIVE, REDWOOD CITY	/s/ Kristopher L. Hanson, Attorney-in-Fact	27 Oct 2025	0001658918

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
holding	MPLT	Voting Common Stock						1,601,164	25 Oct 2025	Direct	F1, F2
holding	MPLT	Voting Common Stock						101,190	25 Oct 2025	See footnote	F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	MPLT	Series C Preferred Stock							25 Oct 2025	Voting Common Stock	3,895		Direct	F4
holding	MPLT	Stock Option (Right to Buy)							25 Oct 2025	Voting Common Stock	98,448	$2.86	Direct	F5
holding	MPLT	Stock Option (Right to Buy)							25 Oct 2025	Voting Common Stock	77,380	$5.55	Direct	F6
holding	MPLT	Stock Option (Right to Buy)							25 Oct 2025	Voting Common Stock	49,107	$5.55	Direct	F7

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Includes 1,601,164 Restricted Stock Units (RSUs). Of the RSUs, (i) as to 237,517 RSUs, 143,500 vested in connection with the Issuer's IPO and the remainder will vest in quarterly installments through July 1, 2027; (ii) as to 122,626 RSUs, 66,422 vested in connection with the Issuer's IPO and the remainder will vest in quarterly installments through October 1, 2027, (iii) as to 387,562 RSUs, 169,558 vested in connection with the Issuer's IPO and the remainder will vest in quarterly installments through January 1, 2028; and (iv) as to 853,459 RSUs, 14/48ths will vest on July 1, 2026 and the remainder will vest in 12 quarterly installments thereafter. With respect to all RSUs, vesting is subject to the Reporting Person's continued service through each vesting date.
F2	Each RSU represents a contingent right to receive one share of voting common stock of the Issuer.
F3	The shares are held by the C&M Kroeger Nominee Trust, of which the Reporting Person is co-trustee with his spouse and has voting and dispositive power.
F4	The Series C Preferred Stock is convertible on a 1-for-16.8 basis into voting common stock at any time at the holder's election and will convert automatically upon the closing of the Issuer's IPO and has no expiration date.
F5	Fully vested.
F6	This stock option vests over a period of four years, with 1/4th of the shares underlying the option vested on the one-year anniversary of February 16, 2022, the vesting commencement date, and 1/48th of the shares underlying the option vesting on a monthly basis thereafter, subject to the Reporting Person's continued service through each vesting date.
F7	This stock option vests over a period of four years, with 1/4th of the shares underlying the option vested on the one-year anniversary of March 11, 2022, the vesting commencement date, and 1/48th of the shares underlying the option vesting on a monthly basis thereafter, subject to the Reporting Person's continued service through each vesting date.